课题基金 / 基金详情

Characterization of entry inhibitors in human cervical & rectal tissue models & d

Characterization of entry inhibitors in human cervical & rectal tissue models & d
人宫颈进入抑制剂的表征
批准号:
7418087
负责人:
ROBIN J SHATTOCK
金额:
$4.48万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-06-23 至 2012-05-31

项目摘要

项目成果

ROBIN J SHATTOCK的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The potential role of microbicides in preventing the mucosal transmission of HIV-i has been clearly identified. However, rigorous pre-clinical evaluation of candidate microbicides is essential to the selection of the best compounds for clinical trials, since this will, in the end, provide savings in costs and time, given the expense and length of formal efficacy trials. Concerns with performing efficacy trials with incompletely optimized microbicide candidates have been highlighted by recent failed or halted Phase III trials (COL- 1492, SAVVY and Cellulose Sulphate); these trials have suggested that development and formulation of effective microbicides may not be as easy as first thought. While mononuclear cell cultures and animal models may provide important information for the evaluation of microbicides, anatomical, physiological and immunological issues suggest they may not adequately model events that occur in human mucosal tissue. Therefore a comprehensive program for pre-clinical development of microbicide candidates requires that information be accrued from several different model systems. Hence Dr. Shattock's and Robbiani's groups have developed in vitro models of the earliest events in HIV-i infection of human mucosal tissue and dendritic cell driven HIV-i spread. These models are ideally suited to test the efficacy of agents designed to block HIV-i sexual transmission and have been widely used to evaluate potential microbicide candidates. Furthermore, experiments described here and cross validation with experiments described in project III, may identify potential biomarkers of efficacy, safety and compliance that could inform future clinical trials. In this project, we will use these established models to evaluate the efficacy and compatibility of HIV-i entry inhibitors (alone and in combination) and their formulations. This research will be influenced and guided by work carried out within Core A, and will involve extensive interactions and collaborations with the scientists leading Research Projects II and III. The interactions between the different groups will result in the fasttracking of the most promising inhibitor combinations and formulations for evaluation in the macaque model (Research Project III).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
An RNA vaccines systems approach to Group A streptococcus vaccine discovery
CHARACTERIZATION OF AFE INHIBITORS IN HUMAN CERVICAL/REC
HIV infection of male genital tissue (R21)
HIV infection of male genital tissue
海外基金